Benzinga | Nov 5, 2020 07:48AM EST

Adaptimmune Therapeutics Q3 EPS $(0.04) Beats $(0.25) Estimate, Sales $1.20M Beat $870.00K Estimate

Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.25) by 84 percent. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $1.20 million which beat the analyst consensus estimate of $870.00 thousand by 37.93 percent. This is a 406.33 percent increase over sales of $237.00 thousand the same period last year.